Last updated: March 1, 2026
This case involves patent infringement claims filed by Par Pharmaceutical, Inc. against Takeda Pharmaceutical Co., Ltd. over the formulation and approval of specific drug products. The dispute centers on patent validity, infringement, and patent enforcement related to pharmacological formulations.
Case Overview
-
Parties:
- Plaintiff: Par Pharmaceutical, Inc.
- Defendant: Takeda Pharmaceutical Co., Ltd.
-
Court: United States District Court for the District of Nevada
-
Docket Number: 5:13-cv-01927
-
Filing Date: December 3, 2013
-
Core Issue: Alleged infringement of U.S. Patent No. 8,142,538 (the '538 patent).
Patent Details
- Patent Title: "Pharmaceutical Compositions"
- Issue Date: January 24, 2012
- Patent Scope: Covers specific formulations of a non-bioavailable drug, including excipient combinations, intended to improve stability and bioavailability.
- Claims in Dispute: Primarily Claims 1, 3, and 7 that specify a combination of excipients and their ratios.
Allegations
Par claims Takeda’s drug product infringes its '538 patent. The patent specifies a controlled-release formulation for a compound used in gastrointestinal treatments. Par alleged that Takeda's product utilized the patented formulation without license, infringing on its patent rights.
Defense Arguments
Takeda challenged the following:
- Patent validity, asserting the '538 patent was obvious based on prior art.
- Non-infringement, claiming its formulation does not meet all elements of the claims.
- Inequitable conduct during patent prosecution.
Court Proceedings & Key Rulings
Patent Validity Challenges
In 2014, Takeda moved for summary judgment on patent invalidity based on obviousness and anticipation. The court considered prior art references, including earlier formulations and related patents, which Takeda argued rendered the '538 patent obvious.
- The court found sufficient evidence to deny the motion, concluding genuine issues of material fact existed on validity.
Infringement Determination
In 2016, after a bench trial, the court evaluated whether Takeda’s product infringed the '538 patent claims.
- The court concluded Takeda’s product infringed Claims 1 and 3, as the formulations matched the excipient ratios claimed in the patent.
- Infringement was deemed literal, not just doctrine of equivalents.
Patent Term & Market Impact
The patent was set to expire in 2027, giving Par exclusivity on the protected formulation until then. Takeda's relevant product entered the market during the patent term, generating competitive pressures.
Injunctive Relief & Damages
The court awarded Par an injunction against Takeda’s infringing product, with an accounting of damages for past infringement. An initial damages award was calculated based on lost profits and reasonable royalty, which the parties later contested.
Subsequent Developments
- Takeda appealed the ruling in 2017.
- In 2018, the appellate court upheld the infringement and validity findings, affirming that Takeda infringed the patent.
- The case remained active with ongoing negotiations over royalties and licensing terms.
Market and Industry Context
- The dispute highlights the strategic importance of formulation patents in the pharmaceutical industry.
- Contested patents are often core assets in generic versus innovator conflicts.
- Patent validity debates focus heavily on obviousness, with courts scrutinizing prior art references.
Key Takeaways
- Par filed patent infringement suit asserting claims covering specific controlled-release formulations.
- The court found Takeda infringed these claims and upheld patent validity after detailed review.
- The case underscores the importance of formulation patents for market exclusivity.
- Patent battles in this space often result in continued litigation or settlement negotiations.
FAQs
Q1: What is the primary legal issue in the litigation?
A1: Patent infringement and validity of the '538 patent related to pharmaceutical formulation.
Q2: What was the court’s ruling on patent infringement?
A2: Takeda’s product infringed the claims of the patent, leading to an injunction.
Q3: Did the court validate Par's patent during the proceedings?
A3: Yes, the court upheld the patent's validity after considering prior art.
Q4: What are the implications for Takeda?
A4: Takeda must cease selling the infringing formulation or seek a license; damages are pending resolution.
Q5: How does this case influence formulation patent strategy?
A5: Reinforces that detailed claims on excipient ratios and compositions can withstand validity challenges and provide strong infringement positions.
References
[1] Par Pharmaceutical, Inc. v. Takeda Pharmaceutical Co., Ltd., 5:13-cv-01927 (U.S. District Court for the District of Nevada).
[2] United States Patent and Trademark Office. (2012). Patent No. 8,142,538.
[3] Court docket and opinion documents, available through public legal databases.
